Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | OneWorld Health acquires pro-drug technology patent from EisaiWill be used to develop a new anti-diarrheal drug for use in the developing world
By: OneWorld Health Diarrheal disease is the second most common cause of death among children under five years of age, with a pediatric death toll of 1.3 million lives lost each year. While oral rehydration therapy (ORT) remains a key part of diarrhea treatment, it has limitations, which iOWH032 is designed to address. Last spring, OWH announced that iOWH032 entered phase 1 clinical trials in the United States, which are now nearly completed. Phase 2 trials are expected to begin in South Asia in 2012. “While oral rehydration therapy is extremely useful, it does not treat the cause of diarrhea directly. Our new anti-secretory drug, iOWH032, is designed to work differently. By targeting the diarrhea directly—not just the resulting dehydration— The original water-soluble pro-drug technology was developed by scientists at the University of Kansas (KU), and the exclusive patent right is owned by the KU Center for Technology Commercialization, Inc. (KUCTC). KUCTC licensed the patent to Eisai, and both parties generously agreed to Eisai sublicensing the rights to OWH. About OneWorld Health Headquartered in South San Francisco, OneWorld Health is a nonprofit drug development program with a mission to discover, develop, and deliver safe, effective, and affordable new treatments for diseases disproportionately affecting people in the developing world. For more information, please visit www.oneworldhealth.org. OneWorld Health is an affiliate of PATH, an international nonprofit organization that transforms global health through innovation. To learn more about PATH, visit www.path.org. About Eisai Co., Ltd. Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops, and markets products throughout the world. Through a global network of research facilities, manufacturing sites, and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. For more information about Eisai Co., Ltd., please visit www.eisai.com/ About the University of Kansas and the Center for Technology Commercialization, Inc. The University of Kansas (KU) is one of the largest research universities in the United States. It has a strong tradition of effective technology commercialization based primarily on research in drug development and delivery; education and human development; Media Contact Elena Pantjushenko Associate, External Affairs, OWH Office: +1 650-392-2537 Mobile: +1 415-341-4140 epantjushenko@ # # # About OneWorld Health Headquartered in South San Francisco, OneWorld Health is a nonprofit drug development program with a mission to discover, develop, and deliver safe, effective, and affordable new treatments for diseases disproportionately affecting people in the developing world. For more information, please visit www.oneworldhealth.org. End
Account Email Address Disclaimer Report Abuse
|
|